Chemours Co (CC) Form 10-Q — Nov 5, 2026
Chemours reported Q3 2026 net income of $196 million, or $1.29 per diluted share, on net sales of $1,540 million, versus revised net income of $46 million ($0.31 EPS) on $1,495 million in sales a year ago. The quarter benefited from $150 million recognized in SG&A from the PFAS Insurance MOU and $51 million of other income. Despite the strong quarter, Chemours remains in a nine-month net loss position of $107 million (-$0.71 EPS), driven partly by a $307 million tax provision, including $228 million of deferred tax charges. Cash of $698 million plus $953 million of revolver availability covers $1,777 million of current liabilities through at least November 2027, per management.
Key figures
- Eps
- 1.29
- Revenue
- 1540
- Net Income
- 196
- Total Debt
- long-term debt, net of $3,783M plus $50M current maturities
- Revenue Yoy
- Q3 2026 net sales of $1,540M vs $1,495M in Q3 2025 (~3% growth); nine months $4,512M vs $4,478M
- Total Assets
- 7293
- Cash Position
- 698
- Shares Outstanding
- 150534489
- Gross profit q3
- 231
- Accrued litigation
- 553
- Revolver availability
- 953
- Q3 2025 eps as revised
- 0.31
- Operating cash flow nine months
- 263
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.